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ABSTRACT: A conformationally constrained short peptide designed to target a protein-protein interaction hotspot in HIV-1 re-
verse transcriptase (RT) disrupts p66-p51 interactions and paves the way to the development of novel RT dimerization inhibitors.
Human immunodeficiency virus type 1 (HIV-1) reverse 
transcriptase (RT) plays a crucial role in the life cycle of 
HIV-1 and is a key target for antiretroviral therapy.1 The ma-
jority of currently approved anti-HIV-1 RT drugs interfere 
with the DNA polymerase activity of the enzyme. However, 
drug resistance and other undesired side effects highlight the 
need to identify novel classes of inhibitors that interact with 
this enzyme by alternative mechanisms.1-3  
The mature HIV-1 RT is a heterodimer composed of 66- 
and 51-kDa subunits, designated as p66 and p51, respectively 
(Figure 1).4,5 Although both subunits bind to the nucleic acid 
substrate, the p66 subunit possesses both DNA polymerase 
and RNase H activities whereas the p51 subunit provides 
structural support to p66 by stabilizing the dimer interface and 
promoting its loading onto the template primer.4-9  
Since HIV-1 RT is an obligate dimer,9,10 inhibition of the 
dimerization process constitutes an alternative approach to 
conventional RT inhibitors that compete with the incoming 
nucleotide substrate, prevent DNA chain elongation, or induce 
a detrimental conformational change in the enzyme active site. 
Disrupting the interactions that stabilize the p66/p51 dimer is 
very challenging and although several RT dimerization inhibi-
tors have been reported9,11,12 this type of inhibitors has not 
reached the clinic yet. Representative examples include short 
peptides mimicking the major contact areas of different inter-
facial regions of the p66/p51 heterodimer such as the 19-mer 
of sequence FKLPIQKETWETWWTEYWQ and its truncated 
10-mer variant of sequence KETWETWWTE. These synthetic 
tryptophan-rich peptides derived from the tryptophan repeat 
motif in the connection subdomain of p66 between positions 
384-407 of p66 were found to be HIV-1 RT inhibitors.11,13 
Although the 19-mer was shown to inhibit the association of 
RT subunits in vitro, it was unable to promote dissociation of 
the heterodimer.11 The 10-mer proved to be more effective as 
an RT dimerization inhibitor13 and it was proposed that it 
interacts in a cleft between the fingers and the connection 
subdomains of p51 thereby destabilizing the dimer confor-
mation and triggering dissociation.12 Prof. Botta’s team report-
ed some small molecules that inhibited, in a dose-dependent 
manner, the HIV-1 RT dimerization process by reducing the 
association of p66 and p51 subunits.14,15 These molecules, of 
which MAS0 (Figure 1) is considered the prototype, were 
obtained by a virtual screening approach in the p66 binding 
pocket defined by Trp402 and Trp410, followed by optimiza-
tion.14,15 MAS0 and analogues inhibited the RNase H and 
polymerase activities of the enzyme. 
The RNase H domain of p66 and the p51 thumb subdomain 
make up a second dimerization interface that plays an im-
portant role in the maturation of the enzyme. A peptide con-
taining the thumb subdomain residues 284-300 
(RGTKALTEVIPLTEEAE) was found to inhibit the RT’s 
DNA polymerase activity while preventing RT maturation and 
blocking HIV replication in cell culture.16 A third important 
p66/p51 interacting region involves a β-hairpin loop in the 
fingers subdomain of p51 that is flanked by Pro133 and 
Pro140.17,18 This so-called 7-8 loop interacts with the palm 
domain of p66 and contributes to the stability of p51/p66 




Figure 1. Three-dimensional crystal structure of HIV-1 RT 
heterodimer and spatial location of the 7-8 loop of the p51 
subunit in the fingers subdomain and of the Trp repeat motif in 
the connection subdomain of the p66 subunit. Interaction sites 
for TSAO-T and MAS0 small-molecule dimerization inhibi-
tors. 
 
The loop is also part of the “floor” of the non-nucleoside RT 
inhibitors (NNRTIs) binding pocket.8,10 
A few years ago we reported on some small molecules that 
interact at the p51 subunit and destabilize the HIV-1 RT 
p66/p51 interaction.17,20,21 In particular, TSAO-T (the proto-
type of a unique family of allosteric NNRTIs)17,20,21 was shown 
to destabilize the heterodimeric HIV-1 RT and decrease its 
ability to bind DNA (Figure 1).22 Therefore, TSAO-T was the 
first example of a small non-peptide molecule that inhibits the 
dimerization process of the enzyme upon transient binding to 
the 7-8 of the p51 subunit.23-26 On the basis of results from 
computational studies it was proposed that TSAO molecules 
bind at the p66/p51 dimer interface, making extensive use of 
the 7-8 loop of the p51 subunit.26 In fact, a key interaction 
for TSAO molecules binding to HIV-1 RT involves Glu138 in 
the 7-8 loop27 and TSAO derivatives consistently select for 
a E138K resistance mutation in HIV-1 RT, hence this loop 
was identified as a “hot spot” for enzyme dimerization.26 In 
addition, the crystal structure of the HIV-1 RT/TSAO-T com-
plex showed a hyperexpansion of the NNRTI-binding pocket 
(NNIBP) and a significant rearrangement of RT subdomains.28 
Consequently, taking together the crystal structure, molecular 
modeling, resistance data and biochemical results, it seems 
reasonable to assume that Glu138 and surrounding residues in 
the 7-8 loop of p51 may form a transient site for binding of 
TSAO inhibitors prior to their final docking inside the NNIBP. 
A segment of the 7-8 loop has a sequence (SINNETPG) 
that is unique for HIV-1 RT. Amino acids of this loop in p51 
(Ile135, Asn136, Asn137, Glu138 and Pro140) make contact 
with the p66 subunit (including P95) and contribute signifi-
cantly to the dimerization binding energy13,15,17 (Figure 2). 
Four of these residues (Asn136, Asn137, Glu138, and Thr139) 
establish several hydrogen bonding interactions with amino 
acids in the p66 subunit19 while Asn136 plays a key role in 
heterodimer stability.29 Due to the dual donor/acceptor charac-
ter for hydrogen bonding of the carboxamide side chain of 
Asn136 this amino acid can make two hydrogen bonds to p66 
backbone CO and NH groups of His96. Moreover, the back-
bone of p51 Asn136 also interacts through hydrogen bonds 
with Thr181 and Val381 of the p66 subunit. On the other 
hand, Glu138 (key residue for TSAO molecules) interacts with 
the side chains of Tyr181 and Lys103 of the p66 subunit, thus 
contributing to the heterodimer’s stability.21,26 Nonconserva-
tive substitutions of those amino acids29-32 must have a large 
impact on the RT heterodimer interface because they often 
render catalytically inactive enzymes.27-29 Alanine-scanning 
mutagenesis of Ser134, Ile135, Asn136, Asn137, Thr139 and 
Pro149 residues31 corroborated the pivotal role of Asn136 in 
HIV-1 RT heterodimer stability and function.30-32 
 
 
Figure 2. Relevant intramolecular hydrogen bonds that help 
to maintain the secondary structure of the p51 β7/β8 loop in 
the p66-p51 heterodimer. The H-bonds surrogated by covalent 
bonds in the designed peptides 4, 5 and 6 are highlighted. 
 
Collectively, the published data summarized above strongly 
suggest that the 7-8 loop of the p51 subunit of HIV-1 RT 
plays a key role in enzyme dimerization and could be a novel 
and attractive pharmacological target for RT inhibition. Our 
previous models and site-directed mutagenesis results19-22 
inspired the design of several novel constrained “minimalistic” 
peptides containing part of the 7-8 loop sequence (Chart 1). 
We herein report their synthesis, NMR and molecular dynam-
ics conformational studies, and biological evaluation. Our 
results provide proof of concept that this largely unexplored 
region of the HIV-1 RT interface is a druggable target thereby 
supporting further studies that can lead to novel classes of RT 
dimerization inhibitors. 
The rational design of synthetic peptides derived from the 
p51 7/8 loop of the native protein was based on two general 
considerations: (1) the conformational features of the -turn 
region and the residues important for dimerization should be 
conserved and (2) the backbone flexibility of the peptides 
should be minimized to maintain and stabilize the bioactive 
conformation. To this end, the three-dimensional structure of 
HIV-1 RT19 provided important information for the design of 
peptides interfering with the dimerization process of this en-
zyme. A detailed analysis of many crystallographic structures 
revealed the presence of two consecutive -turns in the central 
INNE sequence of the -hairpin and up to eight intramolecular 
hydrogen bonds within the 130-144 stretch (Figure 2). The 
two consecutive -turns appear structured by virtue of hydro-
gen bonds between the hydroxyl group of the side-chain of 
Ser134 and the backbone oxygen of Thr139 and also between 
the backbone carbonyl oxygen of Ser134 and the backbone 









Since the double -turn should be preserved in the novel de-
signed peptides, we focused on the synthesis of restrained 
peptides based on the linear peptide 1 (Chart 1). Linear pep-
tides are known to be flexible and proteolytically unstable. In 
contrast, conformationally restrained free peptides usually 
overcome these limitations in solution.33,34 Two strategies 
were followed to introduce those restraints in their confor-
mation. First, the turn-forming DPro-LPro template35 was intro-
duced at the sequence termini to link Phe131 and Tyr146 and 
produce the cyclic peptide 2 (Chart 1). The 17-mer 2 was 
synthesized by solid phase peptide chemistry, followed by 
macrocyclization, deprotection and cleavage (see Supporting 
Information). The second strategy involved the introduction of 
disulfide linkages as surrogates of the three hydrogen bonds 
highlighted in Figure 2. Thus, the disulfide-containing cyclic 
13-mer 4 was prepared by introducing cysteine residues at the 
two ends of the linear peptide (3, IPSINNETPGI) correspond-
ing to residues 130-144 (Chart 1). The disulfide bond in 4 thus 
acts as a surrogate of the hydrogen bond formed between the 
carbonyl oxygen of Phe130 and the amide nitrogen of Tyr144 
(O=C(F130)− HN(Y144), Figure 2).  
 
Chart 1. Sequences of the designed peptides derived from 




Preliminary testing revealed that only the disulfide-
containing cyclic peptide 4 showed some inhibition of HIV-1 
RT polymerase activity whereas the DPro-LPro-containing 
peptide 2 and the linear peptides 1 and 3 were inactive. In light 
of these findings, and with the aim of determining the minimal 
sequence required for biological activity, we also designed and 
studied some truncated disulfide-containing cyclic peptides. 
Our strategy for further optimization involved the replacement 
of the hydrogen bond established between the side chain of 
Ser134 with either the carbonyl oxygen or the amide proton of 
Thr139 (O(S134)-O=C(T139) or O(S134)-HN(T139) re-
spectively, Figure 2). Thus, the 13-mer was truncated to yield 
the cyclic 9-mer 5 (CSINNETPC) and the cyclic 6-mer 6 
(CINNEC) (Chart 1) which could better mimic the bioactive 
conformation observed for the 7/8 loop in the crystallo-
graphic studies. 
It has been reported that by using differential scanning fluo-
rimetry (DSF) it is possible to determine whether an RT inhib-
itor is a destabilizer or stabilizer of the p51/p66 heterodimer 
by the decrease or increase, respectively, caused in the melting 
temperature (Tm).
36 Compounds binding close to the p51/p66 
heterodimer interface have been reported to reduce the Tm of 
RT.37 Thus, to determine if 1-6 were able to stabilize or desta-
bilize the p51/p66 RT heterodimer, we studied the effects of 
these peptides on the thermal stability of HIV-1 RT p51/p66 
heterodimer by performing DSF experiments. The results are 
shown in Table 1 in which MAS4 (an analogue of the HIV-1 
RT dimerization inhibitor MAS0)14,15 and TSAO-T are in-
cluded as reference compounds. As shown in Table 1, an 
important Tm decrease (Tm = 13.6─15.8 °C) was observed in 
the presence of 1-6 that was much larger than that obtained 
with the reference compounds MAS4 and TSAO-T (Tm = 
2.6 and 1.4 °C, respectively). Thus, at 100 µM, 1-6 destabilize 
the RT heterodimer in a way that is consistent with their puta-
tive binding to the heterodimer interface. 
 
Table 1.  Tm detected for the signal of ligand-bound RT and 




RT WT 54.6 ± 0.2  
TSAO 53.2 ± 0.3 - 1.4 
MAS4 52.0 ± 0.3 - 2.6 
1 40.1 ± 0.2 - 15.6 
2 39.6 ± 0.3 - 15.0 
3 41.0 ± 0.2 - 13.6 
4 41.0 ± 0.7 - 14.5 
5 38.8 ± 1.1 - 15.8 
6 38.8 ± 0.5 - 15.8 
aTm (-dI/dT max). bShift in HIV-1 RT melting temperature 
measured in the presence of ligand. Tm values are the average 
of three independent measurements. 
 
Inhibition of HIV-1 RT dimerization was assessed by using 
a previously described high-throughput (HTS) screening assay 
based on the interaction of p66 and p51 containing a FLAG 
epitope and a poly-histidine tail, respectively.25 Briefly, after 
immobilization of the His-p51 subunit on nickel-coated plates 
(HIS-Select®, Sigma) and addition of purified FLAG-p66, the 
extent of dimerization is estimated in an ELISA using specific 
primary antibodies that recognize the FLAG epitope located at 
the N-terminus of p66. When these assays were carried out in 
the presence of 3-6, the linear peptide 3 did not inhibit RT 
dimerization whereas cyclic peptides 4-6 were active in the 
micromolar range (Table 2). The best inhibitor was the cyclic 
hexapeptide 6 with an IC50 of 37 ± 14 μM. 
 
Table 2. Inhibition of HIV-1 RT dimerization and DNA 














1 ND >145 ND 
2 ND >145 ND 
3 >150 >145 ND 
4 137 ± 34 >145 >250 (<5) 
5 61 ± 15 >145 >250 (43) 
6 37 ± 14 109.4 ± 30.8 203 ± 35 
aValues were determined with the FLAG-p66/His-p51 di-
merization assay.25 b Single nucleotide incorporation assays 
were carried out with D38/25PGA, a 38/25mer DNA/DNA 
template primer, and wild-type HIV-1 RT. Reported values are 
the average ± S.D. of three independent experiments. Nevirap-
ine was used as control in these assays and showed an IC50 of 
0.57±0.14 µM. cThe amount of polymerized DNA was deter-
mined after addition of [3H]dTTP, using poly(rA)/oligo(dT)16 
as template-primer. The RT was pre-incubated with the corre-
sponding inhibitor, in the presence or absence of 14% acetoni-
trile for 15 h at 37 ºC. Before adding the nucleotide, acetoni-
trile concentration was reduced to <1% to measure the amount 
of reassociated heterodimer through its enzymatic activity. 








3 (linear)  IPSINNETPGI
 
experiments. Numbers within parentheses represent the per-
centage of inhibition at 200 µM. ND, not determined. 
Although the peptides mimicking the 7/8 loop were able 
to inhibit HIV-1 RT dimerization, they had little impact on the 
RT-associated enzymatic activities. As expected, the RNase H 
activity was not affected by the presence of 1-6 at concentra-
tions as high as 100 μM (the highest concentration tested in 
these assays). However, single nucleotide incorporation assays 
carried out with a 38/25-mer DNA/DNA template-primer 
showed that 6 was able to inhibit the reaction although at 
relatively high concentrations (IC50 = 109.4 ± 30.8 μM) (Table 
2). Other tested oligopeptides showed less than 5% inhibition 
at concentrations above 145 µM in these assays. We also 
found that 6 interferes with the recovery of the DNA polymer-
ase activity after re-association of p66 and p51 in assays car-
ried out with poly(rA)/oligo(dT)16. Full dissociation of the 
HIV-1 RT heterodimer to folded monomers can be achieved in 
the presence of acetonitrile at concentrations in the range of 
12-20%.10 However, this process is reversible and if the con-
centration of acetonitrile is reduced below 1%, a significant 
amount of DNA polymerase activity can be recovered.  
We carried out assays in which HIV-1 RT subunits were 
dissociated in the presence of 14% acetonitrile. After 15 h of 
incubation in the presence or absence of inhibitor (4-6 in these 
assays), acetonitrile concentrations were quickly reduced to 
<1% and primer elongation activity was measured using 
[3H]dTTP. Control assays were carried out in the absence of 
acetonitrile. While 4 had no effect on the recovery of DNA 
polymerase activity at concentrations as high as 250 µM, 6 
showed an IC50 of 203 ± 35 μM (Table 2). These results are 
consistent with those obtained from single-nucleotide incorpo-
ration and FLAG-p66/His-p51 dimerization inhibition experi-
ments, and therefore provide further support to our contention 
that the pocket in p66 harboring the 7/8 loop of p51 is a 
target for RT dimerization inhibitors. 
 
 
Figure 3. (A) Bar plot showing the H (H = Hobserved - 
HRC, ppm) values for residues 134-138 for peptides 3-6 in aque-
ous solution at pH 5.5 and 5 ºC. The random coil (RC) range38 is 
indicated in a grey background. (B) Bar plot showing the tempera-
ture coefficients for the amide protons of residues 134-139. Val-
ues more negative than -4.510-3 ppm·K-1 (grey background) 
indicate solvent-accessible HN protons and those less negative are 
indicative of solvent-protected ones. The inset indicates the bar 
pattern corresponding to each peptide in both panels. 
All oligopeptides including 6 were also tested for their anti-
HIV activity in cell culture and they were shown to be inactive 
at subtoxic concentrations (data not shown), most likely due to 
poor cellular uptake. 
To explain the differences in activity found between linear 
and cyclic peptides, comparative conformational studies in 
aqueous solution using NMR and molecular dynamics (MD) 
simulations were carried out. Once the 1H and 13C chemical 
shifts (Figure S1−S4 and Tables ST1−ST4) of 3-6 in aqueous 
solution were assigned, NOE connectivities, 1H and 13C chem-
ical shifts, and amide temperature coefficients were examined 
to determine the structures adopted by the peptides.38 Since the 
linear peptide 3 (residues 132-142) displays 1H, 13C and 
13C chemical shifts deviations (Figures 3A and S5), amide 
temperature coefficients (Figure 3B and Table ST5) within the 
random coil range (|H| ≤ 0.05 ppm, (|C| ≤ 0.04 ppm, 
|C| ≤ 0.05 ppm, |/T| ≥ 4.5 x 10
-3 ppm·K-1) and no de-
tectable non-sequential NOE, we conclude that it is mostly a 
random coil in solution. In contrast, the NMR data for cyclic 
4-6 clearly indicates that they exhibit some preferred ordered 
conformations. The H, 13C and 13C chemical shift devia-
tions for some residues of the cyclic peptides are large (Fig-
ures 3A and S5), particularly in the case of the shortest peptide 
6. The amide temperature coefficients of residues N137 and 
E138 in the cyclic peptides exhibit values that are below -4.5 
ppm·K-1 (Figure 3B and Table ST5) and hence are strongly 
suggestive of low solvent accessibility and involvement in 
intramolecular hydrogen bonding, as observed in many X-ray 
crystal structures (e.g. PDB id. 1DLO). Furthermore, the cy-
clic peptides display non-sequential NOEs and dihedral angles 
derived from the 1H, 13C and 13C chemical shifts (Tables 
ST1, ST6, and ST7) that support well-defined 3D structures 
comparable to that of 7/8 loop in the p51 subunit of HIV-1 
RT, particularly in the case of the minimalistic cyclic peptides 
4 and 6 (Figures 4 and S6). 
 
 
Figure 4. Superposition of the 7/8 loop in p51 as found 
in a representative X-ray crystal structure of HIV-1 RT (in 
grey, PDB id. 1DLO) and the NMR-derived average structure 
of cyclic peptides (A) 6 (green), (B) 5 (magenta), and (C) 4 
(cyan). Only the backbone atoms of residues 134-139 were 
considered. Residues I135, N136, N137, and E138 are labeled. 
In the cyclic peptides, the Cys disulfide linkages are shown in 
yellow. RMSd = root-mean-square deviation. 
 
Three independent unrestrained MD simulations for 4−6 in 
explicit water, each lasting 200 ns (i.e. 0.6 µs per peptide), 
were also run in explicit aqueous solution starting from con-
formations derived from the 7-8 loop of HIV-1 RT.4 The 
evolution of the root-mean-squared deviation (RMSd, Å) of 
the central INNE amino acid stretch provided a measure of the 
structural stability, which showed values <0.5 Å for most of 
the time (Figure S7). In other words, the cyclic peptides main-
tain an overall conformation close to that found in the 7-8 
loop of HIV-1 RT, even in the absence of the enzyme. In all of 
these peptides, the S134−I135 and N137−E138 intramolecular 
NH−O=C hydrogen bonds are kept for almost the whole 
 
length of the MD simulations (Figure S8), in excellent agree-
ment with the NMR data showing strong protection of the 
NH(E138)–O=C(I135) from the solvent in 4 and 6. These two 
peptides display  and  angles very close to those found in 
the 7-8 loop of HIV-RT p51 subunit although some residues 
can also temporarily visit other regions of the Ramachandran 
plot throughout the MD simulation time (e.g. E138 in 4 and 6, 
or N136 in 5 (Figure S9). This is because the absence of any 
restraints in our MD simulations allowed the identification of 
other minor conformations that are only transiently visited 
(Figure S10). In any case, both the NMR experiments and the 
theoretical studies show that the central region of the three 
peptides can adopt a three-dimensional structure that resem-
bles that of the p66-bound 7-8 loop of the p51 subunit of 
HIV-1 RT. 
Finally, by measuring some extra intramolecular hydrogen 
bonds beyond the INNE motif in the larger cyclic peptides 4 
and 5 (Figure S11), we identified a major cluster of conform-
ers of 5 displaying two additional intramolecular hydrogen 
bonds, one between O(S134) and HN(T139) and another 
between O(T139) and HN(C133). The former is present in the 
native protein but the latter is novel because in the p51 subunit 
that amide proton is absent because Pro133 occupies that 
position. Interestingly, the latter hydrogen bond occurs be-
tween O(S134) and HN(T139) in 4.  
Taken together, our results show that, amongst the peptides 
synthesized to mimic the 7-8 loop of the p51 subunit of 
HIV-1 RT with the aim of inhibiting enzyme dimerization, the 
cyclic peptides 4−6 adopt structures in aqueous solution that 
are highly similar to that observed in the native protein and 
preserve some of the intramolecular hydrogen bonds present in 
the loop. In contrast, linear peptides 1 and 3 show random 
conformations in solution. In vitro evaluation of these peptides 
revealed that 6 can actually destabilize the HIV-1 RT dimer 
and also moderately inhibit the DNA polymerase activity of 
this enzyme. These results provide proof of concept that the 
identified hotspot at the p66-p51 interface is druggable and 
pave the way to the development of novel RT dimerization 
inhibitors. 
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Conformationally constrained short peptides were designed to target a protein-protein interaction hotspot in HIV-1 reverse 
transcriptase (RT) to disrupt p66-p51 interactions.  
 
 
 
p66
p51
